Transfection with thehERG1cDNA (Fig

Transfection with thehERG1cDNA (Fig. by blocking Vascular Endothelial Growth Factor-A [VEGF-A; reviewed in5], which has a pivotal role in the angiogenic switch6. Accordingly, the first angiogenesis inhibitor to be approved for therapy was the monoclonal anti-VEGF-A antibody bevacizumab7. The second generation drugs are instead inhibitors of receptor tyrosine kinase (RTK), which regulate angiogenesis in a less direct way8. However, maximizing the efficacy of anti-angiogenic therapy turned out to be more challenging than expected9. Differently from what was observed in pre-clinical studies, bevacizumab only improves clinical outcome when combined with chemotherapy, in part because it normalizes tumor vessels and improves drug delivery10. However, the greatest therapeutic challenge today is perhaps surmounting the intrinsic tumor resistance to anti-angiogenic drugs and avoiding the rapid re-growth of tumor vessels (with relapse of tumor growth) generally observed on withdrawal from anti-angiogenic treatment11. The mechanisms of intrinsic refractoriness as well as acquired resistance to treatment can be partly attributed to the neoplastic cells themselves, which can Rabbit Polyclonal to RPS23 produce and release alternative angiogenic factors12. Moreover, the tumor microenvironment (TM) can promote escape from VEGF-targeted therapy13, mainly through the onset of hypoxia14. The hypoxic TM stimulates activation of the Hypoxia Inducible Factors [HIFs13,15,16], which in turn up-regulate the transcription ofVEGF-A6,17,18, as well as of many tumor progression genes14. It is worth recalling that in cancer, the expression of HIFs and the subsequent secretion of angiogenic factors can be also abnormally up-regulated under normoxic conditions by different pathways13,19,20, mainly involving Akt and its downstream effectors21,22. Such process is known as hypoxic mimicry23. For example, this can result from mutations of the VHL protein24or from activation of different oncogenes, such as those coding for plasma membrane receptors that regulate the phosphatidyl inositol-3-kinase (PI3K) and hence Akt25,26,27. The TM also comprises the extracellular matrix (ECM) and its receptors, mainly integrins28, which represent functional hubs, capable to integrate signals in a bi-directional manner between the TM and the intracellular space of tumor cells (reviewed in29). In some cases, integrin function depends on the formation of macromolecular complexes which comprise other membrane receptors, thus constituting signaling platforms at the adhesive sites30. An interesting recent development of these studies is the observation that such membrane complexes often include ion channels31,32. In general, increasing evidence supports the notion that ion channels and transporters control the development of cancer hallmarks in different human cancers33,34,35,36. In particular, we previously showed that the K+channels encoded by the humanether–go-go related gene(Kv11.1, or hERG1) are often aberrantly expressed in human cancers37. In these, hERG1 controls different aspects of the neoplastic cell physiology as it triggers and modulates intracellular signaling cascades38through the assembly INH6 of multiprotein membrane complexes which also recruit integrin subunits39and receptors for growth factors40or chemokines41. Therefore, hERG1 may be an indispensable component of the functional hubs that control tumor angiogenesis39,42. Based on these premises we hypothesized that the TM, through the functional interplay between integrins and hERG1, regulates angiogenesis and tumor progression and that this mechanism could INH6 contribute to VEGF resistance. Here, we test this hypothesis in CRC cells, because hERG1 is expressed in CRCs43and is a negative prognostic factor in non metastatic patients44. == Results == == 1integrins and hERG1 channels form a functional plasma membrane complex == We first determined whether the physical and functional association between hERG1 and the 1subunit of integrin receptors (hereafter 1) found in several tumor cell lines45,46,39also occurs in CRC cells. Several CRC cell lines were characterized for the expression of 1and hERG1 (Supplementary Table 1 (Table 1S). All of them expressed significant amounts of the 1integrin subunit, but variable levels of functional hERG1 channels. The highest level of hERG1 INH6 was observed in HCT116 cells, the lowest in HT29 (Table 1SandSupplementary Fig.1 (Fig. 1S)). Next, 1was engaged by either cell adhesion onto either fibronectin (FN) or an anti 1activating antibody (TS2/16). Data relative to HCT116 cells seeded onto TS2/16 are reported inFig. 1A. 1engagement increased the hERG1 current density (Fig. 1Aupper panel), reaching average amplitudes of more than 3 pA/pF at 120 mV,.